CoChat

Durability of Addition of Roux-en-Y Gastric Bypass to Lifestyle Intervention and Medical Management in Achieving Primary Treatment Goals for Uncontrolled Type 2 Diabetes in Mild to Moderate Obesity: A Randomized Control Trial

Open access

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: We compared 3-year achievement of an American Diabetes Association composite treatment goal (HbA1c <7.0%, LDL cholesterol <100 mg/dL, and systolic blood pressure <130 mmHg) after 2 years of intensive lifestyle-medical management intervention, with and without Roux-en-Y gastric bypass, with one additional year of usual care. RESEARCH DESIGN AND METHODS: A total of 120 adult participants, with BMI 30.0–39.9 kg/m2 and HbA1c ≥8.0%, were randomized 1:1 to two treatment arms at three clinical sites in the U.S. and one in Taiwan. All patients received the lifestyle-medical management intervention for 24 months; half were randomized to also receive gastric bypass. RESULTS: At 36 months, the triple end point goal was met in 9% of lifestyle-medical management patients and 28% of gastric bypass patients (P = 0.01): 10% and 19% lower than at 12 months. Mean (SD) HbA1c values at 3 years were 8.6% (3.5) and 6.7% (2.0) (P < 0.001). No lifestyle-medical management patient had remission of diabetes at 36 months, whereas 17% of gastric bypass patients had full remission and 19% had partial remission. Lifestyle-medical management patients used more medications than gastric bypass patients: mean (SD) 3.8 (3.3) vs. 1.8 (2.4). Percent weight loss was mean (SD) 6.3% (16.1) in lifestyle-medical management vs. 21.0% (14.5) in gastric bypass (P < 0.001). Over 3 years, 24 serious or clinically significant adverse events were observed in lifestyle-medical management vs. 51 with gastric bypass. CONCLUSIONS: Gastric bypass is more effective than lifestyle-medical management intervention in achieving diabetes treatment goals, mainly by improved glycemic control. However, the effect of surgery diminishes with time and is associated with more adverse events.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc15-2481

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 103

Metadata

Authors
Ikramuddin, S., Korner, J., Lee, W.-J., Bantle, J. P., Thomas, A. J., Connett, J. E., Leslie, D. B., Inabnet, W. B., Wang, Q., Jeffery, R. W., Chong, K., Chuang, L.-M., Jensen, M. D., Vella, A., Ahmed, L., Belani, K., Olofson, A. E., Bainbridge, H. A., & Billington, C. J.
Affiliations
  • University of Minnesota (US)
  • Division of Endocrinology, Department of Medicine, Columbia University Medical Center, New York, NY
  • National Taiwan University Hospital (TW)
  • Mount Sinai Hospital (US)
  • Min Sheng General Hospital (TW)
  • Mayo Clinic (US)
  • Harlem Hospital Center (US)
  • Columbia University Irving Medical Center (US)
Corresponding author
Ikramuddin, Sayeed
Venue
Diabetes Care
Published
2016-06-16
Volume
39
Issue
9
Pages
1510-1518
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2429202482
Cited by
99
References
28
Citations by year
2026: 4 · 2025: 6 · 2024: 5 · 2023: 9 · 2022: 8 · 2021: 7 · 2020: 17 · 2019: 13 · 2018: 14 · 2017: 12 · 2016: 3
FWCI
15.51
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Covidien
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30-DK-050456)
  • National Center for Advancing Translational Sciences (UL1 TR000040, UL1 RR024156)
Topics
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
Roux-en-Y gastric bypass, type 2 diabetes, obesity, lifestyle intervention, medical management, glycemic control, HbA1c, diabetes remission, weight loss, adverse events, bariatric surgery, treatment goals
MeSH terms
Adult, Blood Glucose, Blood Pressure, Combined Modality Therapy, Diabetes Mellitus, Type 2, Female, Goals, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Life Style, Cholesterol, LDL, Male, Middle Aged, Obesity, Remission Induction, Taiwan, Time Factors, United States, Gastric Bypass, Weight Loss, Treatment Outcome, Risk Reduction Behavior

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.